Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Thyroid Cancer: Genetics and Targeted Therapies"
Deadline for manuscript submissions: 21 September 2019.
Dr. Lori J. Wirth E-Mail
Department of Hematology-Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
We write to invite you to contribute to a Special Issue in Genes that will focus on Thyroid Cancer Genetics and Therapies. Thyroid cancer is the most prevalent endocrine malignancy. It affects women three times more frequently than men and ranks as the 5th most common cancer in women in the United States. The number of newly diagnosed thyroid cancers has more than tripled over the past four decades, and the worldwide incidence of the disease continues to steadily rise.
Significant advances in the molecular characterization of thyroid cancer have dramatically improved our understanding of the genetic mechanisms underlying disease development and progression. Genetic testing of thyroid specimens has demonstrated clinical utility in addressing some of the most critical challenges in the field. Molecular analysis of fine needle aspirates (FNA) is having a major impact on the pre-operative diagnosis of thyroid nodules with indeterminate cytology, by helping to discriminate between high-risk cancerous lesions, intermediate/low-risk tumors, and benign thyroid nodules. This molecularly-based risk stratification is being used alongside imaging studies and cytological analyses to guide patient management, which can range from total thyroidectomy with lymph node dissection for high-risk cancer, to periodic observation, thus sparing patients with benign nodules from unnecessary surgery. In the setting of advanced-stage, progressive disease, genetic testing of thyroid tumors is directing systemic treatment decisions by identifying relevant molecular markers associated with response to specific targeted therapies.
In this Special Issue of Genes, we welcome reviews, mini-reviews, new methods, and original research articles that highlight our current knowledge and advance our understanding of thyroid cancer. We welcome studies on all forms of thyroid cancer, including papillary thyroid carcinoma, the most prevalent type, as well as rare tumors, including follicular thyroid carcinoma, Hürthle cell thyroid cancer, poorly differentiated and anaplastic thyroid carcinoma, and medullary thyroid cancer. Topics of interest include but are not limited to the role of genetic and epigenetic alterations, pathological features, and environmental factors in thyroid cancer biology and evolution, and their potential clinical implications for diagnosis, prognosis, and in predicting therapeutic efficacies and outcomes. We also welcome studies that highlight new technologies and non-invasive approaches to monitoring treatment response, early detection of primary disease or recurrence, and identification of mechanisms of acquired resistance to therapy.
We look forward to your contributions.
Dr. Dora Dias-Santagata
Dr. Lori J. Wirth
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- thyroid cancer
- thyroid carcinoma
- genetic abnormalities
- genetic markers
- molecular testing
- fine needle aspiration
- targeted cancer therapy
- systemic therapy
- adjuvant therapy
- oncogenic mutations
- gene rearrangements